These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 2566802)

  • 1. Heart failure responding to octreotide in patient with acromegaly.
    Chanson P; Timsit J; Masquet C; Guillausseau PJ; Warnet A; Lubetzki J
    Lancet; 1989 Jun; 1(8649):1263-4. PubMed ID: 2566802
    [No Abstract]   [Full Text] [Related]  

  • 2. Improvement of congestive heart failure after octreotide and transsphenoidal surgery in a patient with acromegaly.
    Akaza I; Tsuchiya K; Akaza M; Sugiyama T; Izumiyama H; Doi M; Yoshimoto T; Hirata Y
    Intern Med; 2009; 48(9):697-700. PubMed ID: 19420816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resolution of acromegalic cardiomyopathy in mild acromegalic physical abnormality after short-term octreotide therapy.
    Hwang MW; Shimatsu A; Sasaki Y; Ayukawa H; Inenaga K; Takeoka R; Iwase T; Kawai C
    Heart Vessels; 2007 May; 22(3):202-7. PubMed ID: 17533526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma.
    Candrina R
    Recenti Prog Med; 1994 Jan; 85(1):13-9. PubMed ID: 8184174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic profile in patients with acromegaly treated with somatostatin analogue.
    Valea A; Carsote M; Ghervan C; Georgescu C
    J Med Life; 2015; 8 Spec Issue(Spec Issue):82-6. PubMed ID: 26361517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart transplantation for terminal congestive heart failure in an acromegalic patient.
    Albat B; Leclercq F; Serre I; Fille A; Baldet P; Grolleau-Raoux R; Thevenet A
    Eur Heart J; 1993 Nov; 14(11):1572-5. PubMed ID: 8299642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short term use of octreotide in acromegaly.
    John M; Shah NS; Menon PS
    J Assoc Physicians India; 2005 May; 53():477-8. PubMed ID: 16124359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of octreotide treatment on somatic and psychological symptoms of acromegaly.
    Ruchala M; Stangierska I; Gurgul E; Stangierski A; Fajfer J; Sowinski J
    Neuro Endocrinol Lett; 2010; 31(2):265-9. PubMed ID: 20424578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Congestive heart failure worsening with octreotide in acromegalic patient.
    Leclerq F; Fille A; Albat B; Bringer J; Grolleau R; Jaffiol C
    Lancet; 1991 Nov; 338(8777):1272-3. PubMed ID: 1682667
    [No Abstract]   [Full Text] [Related]  

  • 10. Octreotide for acromegaly treatment: a reappraisal.
    Giustina A; Karamouzis I; Patelli I; Mazziotti G
    Expert Opin Pharmacother; 2013 Dec; 14(17):2433-47. PubMed ID: 24124691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term continuous infusion of octreotide in acromegaly. Pharmacokinetics and prediction of the response to long-term treatment.
    Timsit J; Chanson P; Harris AG; Grass P; Guillausseau PJ; Warnet A; Lubetzki J
    Horm Metab Res; 1991 Jan; 23(1):48-9. PubMed ID: 2016081
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute hepatitis after treatment of acromegaly with octreotide.
    Arosio M; Bazzoni N; Ambrosi B; Faglia G
    Lancet; 1988 Dec 24-31; 2(8626-8627):1498. PubMed ID: 2904619
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of acromegaly with SMS 201-995].
    Jorde R; Skare S
    Tidsskr Nor Laegeforen; 1988 Nov; 108(31):2844-5. PubMed ID: 3201449
    [No Abstract]   [Full Text] [Related]  

  • 14. Differential effects of octreotide treatment and transsphenoidal surgery on growth hormone-binding protein levels in patients with acromegaly.
    Hernandez I; Soderlund D; Espinosa-de-los-Monteros AL; Ochoa R; Zarate A; Mercado M
    J Neurosurg; 1999 Apr; 90(4):647-50. PubMed ID: 10193608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
    Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide.
    Page MD; Millward ME; Taylor A; Preece M; Hourihan M; Hall R; Scanlon MF
    Q J Med; 1990 Feb; 74(274):189-201. PubMed ID: 2111918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A risk-benefit assessment of octreotide in the treatment of acromegaly.
    van der Lely AJ; de Herder WW; Lamberts SW
    Drug Saf; 1997 Nov; 17(5):317-24. PubMed ID: 9391775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea.
    Chin SO; Chung CH; Chung YS; Kim BJ; Kim HY; Kim IJ; Kim JG; Kim MS; Kim SY; Lee EJ; Lee KY; Kim SW
    BMJ Open; 2015 Jun; 5(6):e006898. PubMed ID: 26063564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.